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A B S T R A C T
Purpose
BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade
gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains
unknown.
Patients and Methods
A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up
was performed (N = 510). Clinical and treatment data of patients with BRAF V600E mutated PLGG
(n = 99) were compared with a large international independent cohort of patients with BRAF V600E
mutated-PLGG (n = 180).
Results
BRAF V600Emutationwas detected in 69 of 405 patients (17%)with PLGG across a broad spectrum
of histologies and sites, including midline locations, which are not often routinely biopsied in clinical
practice. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and ra-
diation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to
41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively
(P , .001). Additional multivariable clinical and molecular stratification revealed that the extent of
resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG.
A similar independent role forCDKN2A and resection on outcomewere observed in the independent
cohort. Quantitative imaging analysis revealed progressive disease and a lack of response to
conventional chemotherapy in most patients with BRAF V600E PLGG.
Conclusion
BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current
adjuvant therapy.
J Clin Oncol 35:2934-2941. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Pediatric low-grade gliomas (PLGGs) are the
most frequent brain tumors in children1 and
comprise a heterogeneous group of tumors with
different locations, histologic subtypes, ages at
presentation,2 and clinical behavior. In recent
years, the genetic background of PLGGs3 has
begun to be unraveled. Although PLGGs are
genetically quiet and each tumor harbors few
genetic alterations, these ultimately converge on
the activation of the RAS/MAPK pathway,4,5 and
these alterations are commonly mutually exclusive
driving tumor formation. The scarcity of other
genetic alterations in PLGGs is in keeping with
the generally benign behavior; however, the role,
if any, that these alterations play in predicting
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response to therapy and clinical outcome is still not known. As
a result, as far as nonsurgical treatment is concerned, all patients
with PLGGs receive similar treatment independent of their tu-
mor’s molecular alterations.6 For deeply located tumors, such as
hypothalamic/chiasmatic LGGs, the need for biopsy before
treatment decisions are made for these children is still debated.
The BRAF V600E mutation, which is observed in a variety of
adult7 and pediatric neoplasms, is thought to be present in only
a small percentage of PLGGs.8 Controversy still exists as to whether
BRAF V600E-mutant PLGG constitutes a unique subgroup with
respect to natural history and outcome.9,10 We have previously
reported that PLGGs that transform to high-grade gliomas have
a high incidence of BRAF V600E mutations in combination with
CDKN2A deletion.11 CDKN2A is a tumor suppressor gene and
a key regulator of the cell cycle. CDKN2A alterations act as
a secondary hit, which allows for escape from cell cycle regulation
and malignant behavior in multiple cancer types.12,13 In PLGGs,
CDKN2A loss has been reported to be associated with escape from
oncogene-induced senescence,14 especially when combined with
BRAF mutations.
To better define the clinical significance of BRAF V600E in
these tumors, we performed a combined clinical and genetic
analysis in an institutional discovery cohort of patients with PLGG
who were diagnosed and treated in southern Ontario.15 We then
assembled a large multicenter independent cohort of patients with
BRAF V600E-mutated PLGG to study their outcome and response
to therapy.
PATIENTS AND METHODS
Patient Cohort
Clinical data were obtained from The Hospital for Sick Children
(SickKids) institutional PLGG database, which longitudinally observes all
patients in southern Ontario who were diagnosed and treated at SickKids
between January 1985 and December 2015, as previously reported.11,15
PLGGs were defined as any glial or mixed glial-neural tumor, with
the exception of ependymoma, that would be graded as grade I or II
according to the revised 4th edition of the WHO Classification of Tu-
mors of the Central Nervous System. Specifically, pleomorphic
xanthoastrocytoma with anaplasia and subependymal giant-cell
astrocytomas were excluded.
A discovery cohort of all patients with PLGG was assembled for
which tissue and V600E mutation analysis was available (N = 510). To
assess outcome and response to therapy, all 510 patients were analyzed.
To adequately assess the prevalence of BRAF V600E mutations and the
association with location and pathology subtypes, tumors that were
diagnosed between 2000 and 2015 (n = 449) were analyzed, as 90% of the
patients (n = 405) had available molecular data to test for PLGG mu-
tations (Table 1). For outcome of BRAF V600E PLGG, an independent
cohort of patients with BRAF V600E-mutated PLGG was assembled
from 18 collaborating international pediatric centers. The study was
approved by the SickKids research ethics board and that of all par-
ticipating institutions.
The extent of surgical resection, radiation, and chemotherapy data
and their association with outcome were assessed in both the SickKids
cohort and independent cohort. To assess the response to chemotherapy,
imaging findings before and 6 months after the initiation of treat-
ment were compared. Progression was defined as the need for treatment
change (ie, surgery, alternate chemotherapy, or radiation) related to
tumor progression on imaging and/or clinical worsening, as previously
described.16-18
Molecular Analysis
For the SickKids cohort, BRAF V600E mutations were determined by
Droplet Digital (DD)-PCR (Bio-Rad, Hercules, CA) and/or by a Clinical
Laboratory Improvement Amendments–approved immunohistochemis-
try test. For the independent cohort, V600Emutations were analyzed using
institutional Clinical Laboratory Improvement Amendments–approved
tests. KIAA1549-BRAF fusion and/or BRAF duplication were evaluated
using NanoString (NanoString, Seattle, WA) and/or fluorescent in situ
hybridization as described previously.16,19
CDKN2A was analyzed using DD-PCR, single-nucleotide poly-
morphism array, or FISH for all available samples. For the independent
cohort, if CDKN2Awas not analyzed locally, we performed the assay using
DD-PCR. We defined CDKN2A deletion as two copy loss by fluorescent
in situ hybridization or the relative value that correlates with two copy loss
as analyzed by single-nucleotide polymorphism array or DD-PCR, taking
into account normal cell infiltration. Additional information on clinical
and molecular parameters is available in the Appendix (online only).
Statistical Analysis
Progression-free survival (PFS) was defined as the interval between
initial diagnosis and the time of progression. Overall survival (OS) was
calculated as the time from diagnosis to the time of death from any cause as
reported by the referring institution.
PFS and OS were analyzed by the Kaplan-Meier method, and P values
are reported using the log-rank test. Survival data are presented as survival
estimates, including 95% CIs. Associations between covariates and risk
groups were tested by using Fisher’s exact test. Univariable and multi-
variable Cox proportional hazards regression was used to estimate hazard
ratios (HRs), including 95% CIs. All P values reported are two sided. All
statistical analyses were performed with the R statistical environment
(version 3.1.2), using R packages survival (version 2.37-7), Regression
Modeling Strategies (version 4.3-1), Cox Regression with Firth’s Penalized
Likelihood (version 1.1), and Create Elegant Data Visualisations Using
Grammar of Graphics (version 1.0.0), as well as SAS (SAS/STAT User’s
Guide, version 9.4; SAS Institute, Cary, NC).
Table 1. Patient and Tumor Characteristics in the SickKids Cohort (patients
from 2000 to 2015)
Characteristic
All Patients
(N = 405)
WT
(n = 336; 83%)
V600E Mutant
(n = 69; 17%)
Sex, %
Male/female 50.6/49.4 51.2/48.8 47.8/52.2
Age, years
Median 8.52 8.08 11.1
Range 0-18.28 0.52-18.28 0-17.46
25th/75th quartile 4.34/12.55 4.05/12.02 6.5/14.32
Location, No. (%)
Hemispheric 157 (100) 114 (72.6) 43 (27.4)
Diencephalic 74 (100) 61 (82.4) 13 (17.6)
Brainstem 39 (100) 33 (84.6) 6 (15.4)
Cerebellum 112 (100) 108 (96.4) 4 (3.6)
Spine 15 (100) 12 (80) 3 (20)
Disseminated 8 (100) 8 (100) 0 (0)
Pathology, No. (%)
Pilocytic astrocytoma 167 (100) 162 (97) 5 (3)
Pilomyxoid
astrocytoma
15 (100) 13 (86.7) 2 (13.3)
Ganglioglioma 51 (100) 26 (51) 25 (49)
PXA 9 (100) 2 (22.2) 7 (77.8)
Diffuse astrocytoma 23 (100) 13 (56.5) 10 (43.5)
LGG NOS 70 (100) 56 (80) 14 (20)
Others 70 (100) 64 (91.4) 6 (8.6)
Abbreviations: LGG NOS, low-grade glioma not otherwise specified; PXA,
pleomorphic xanthoastrocytoma, WT, wild type.
jco.org © 2017 by American Society of Clinical Oncology 2935
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RESULTS
BRAF V600E Is Common in PLGG
Among the 405 patients with PLGG who were treated at
SickKids between 2000 and 2015, 69 (17%) harbored the BRAF
V600E mutation. This analysis included all tumors and not only
patients who required additional postoperative treatment. BRAF
V600E tumors were diagnosed in all ages and originated from
all CNS locations (Table 1). Of importance, the mutation was
common in midline tumors, including optic pathway, brainstem,
and spinal cord tumors. Overall, 33% of BRAF V600E PLGGs
originated in the midline (diencephalon and brainstem). Similarly,
BRAF V600E mutations were observed in most pathologic sub-
types. As expected, the highest incidence of the mutation was
observed in pleomorphic xanthoastrocytoma (78%) followed by
gangliogliomas (49%); however, the mutation was also commonly
observed in diffuse astrocytomas (43%) and WHO grade I as-
trocytomas (20%; Table 1).
BRAF V600E Mutation Confers Poor Outcome With
Conventional Therapies
Long-term survival data were analyzed in 510 patients with
PLGG from the SickKids cohort (mean follow-up, 7 years; range,
0.01 to 28 years).15 In contrast to other PLGGs, BRAF V600E-
mutant tumors (n = 99) continued to progress without reaching
a plateau. Five-year PFS for BRAF V600E-mutant and wild-type
(WT) PLGG was 50.1% (95% CI, 38.1% to 62.1%) and 72.8%
(95% CI, 67.9% to 77.7%), respectively. Furthermore, 10-year
PFS for BRAF V600E-mutant and WT PLGG was 27% (95% CI,
12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%), re-
spectively (HR, 2.04; 95% CI, 1.45 to 2.88; P , .001; Fig 1A).
Continuous late progression was associated with late deaths in
patients with the BRAF-V600E PLGG. Ten-year OS for BRAF
V600E and WT PLGG was 83.9% (95% CI, 72.5% to 95.6%) and
92.1% (95% CI, 88.6% to 95.6%), respectively (HR, 1.57; 95%
CI, 0.80 to 3.14; P = .183; Fig 1B). Of importance, late deaths
related to tumor progression were observed in BRAF V600E
PLGG even at 25 years of follow-up. Furthermore, survival
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Fig 1. Survival of patients from the
SickKids cohort with pediatric low-grade
glioma stratified by BRAF V600E status. (A)
Progression-free survival (PFS) of the Sick-
Kids cohort according to BRAFV600E status.
(B) Overall survival (OS) for the entire Sick-
Kids cohort according to BRAFV600E status.
(C) PFS of the SickKids cohort comparing
BRAF V600E with KIAA1549-BRAF. (D) OS
of the SickKids cohort comparing BRAF
V600E with KIAA1549-BRAF. P values were
determined by using the log-rank test. WT,
wild type.
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analysis revealed that patients with BRAF V600E PLGG faired
significantly worse than those with the BRAF KIAA1549 fusion
(Figs 1C and 1D).
To further examine the causes of poor survival in children
with BRAF V600E-mutant PLGG, the effect of current therapeutic
interventions in the SickKids cohort were tested. Despite gross total
resection (GTR), which was achieved in 44.4% of these tumors,
many patients with BRAF V600E PLGG continued to experience
progression postresection. Five-year PFS for GTR and non-GTR
was 67.8% (95% CI, 46.8% to 88.8%) and 38.8% (95% CI, 24.1%
to 53.5%), respectively (P = .01; Fig 2A). These findings are in
keeping with analysis performed in BRAF WT PLGG in which we
observed a 5-year PFS of 95.9% (95%CI, 92.5% to 99.6%) for GTR
and 53.3% (95% CI, 46% to 61.7%) for non-GTR (P , .001).
Strikingly, PFS was much worse in patients with BRAF V600E
PLGG who achieved GTR compared with patients with BRAF WT
PLGG (P , .001). Similarly, patients with BRAF V600E PLGG
experienced poor outcome postradiation and chemotherapy. Five-
and 10-year PFS postradiotherapy was 42.2% (95% CI, 20.6% to
63.8%) and 28.1% (95% CI, 6.7% to 49.5%), respectively
(Appendix Fig A1A, online only). Thirty-two percent of patients
with BRAF V600E-mutant received chemotherapy. Five-year PFS
after first-line chemotherapy was 30.4% (95% CI, 13.3% to 47.5%;
Appendix Fig A1B).
Copy number status of CDKN2A was available for 403
patients with PLGG from the SickKids cohort. CDKN2A was
deleted in 25% of BRAF V600E PLGGs and 17% of WT PLGGs.
Although CDKN2A deletion resulted in poor survival and PFS
for the entire cohort, this effect was restricted to BRAF V600E
PLGGs (Appendix Fig A2, online only). PFS in children with
BRAF V600E PLGG was 24.0% (95% CI, 1.9% to 46.1%) and
68.7% (95% CI, 52.8% to 70.2%) for the CDKN2A deleted and
balanced tumors, respectively, at 5 years and 0% and 45.9%
(95% CI, 21.6% to 70.2%), respectively, at 10 years (P = .005;
Fig 2C).
To further examine the poor outcome observed in patients
with BRAF V600E PLGG in the SickKids cohort, an independent
cohort of 180 patients with BRAF V600E PLGGwas compiled from
18 large, pediatric neuro-oncology centers. Characteristics of the
independent cohort compared with SickKids patient cohort with
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Fig 2. Survival of patients with BRAF
V600E pediatric low-grade glioma accord-
ing to the extent of resection and CDKN2A
deletion. (A) Progression-free survival (PFS)
of the BRAF V600E SickKids cohort accord-
ing to the extent of resection. (B) PFS for the
BRAF V600E independent cohort according
to the extent of resection. (C) PFS for the
BRAFV 600E SickKids cohort according to
CDKN2A status. (D) PFS for the BRAF V600E
independent cohort according to CDKN2A
status. P values were determined using the
log-rank test. GTR, gross total resection. bal,
balanced; del, deleted.
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the V600E mutation are listed in Appendix Table A1. Overall,
similar poor PFS and OS were observed in patients with the
BRAF V600E mutation (Appendix Fig A3, online only). Of
importance, as observed in the discovery cohort, a lack of complete
resection was associated with poor outcome in patients with
BRAF V600E PLGG (P = .001; Fig 2B), and CDKN2A deletion also
conferred poor outcome in the independent cohort (P = 0.02;
Fig 2D).
An Integrative Prognostic Model for BRAF V600E PLGG
Combining the extent of resection, BRAF V600E and
CDKN2A deletion revealed a high-risk group of patients with
PLGG. In a multivariable Cox proportional hazards regression
model of the discovery cohort, BRAF V600E and the extent of
resection contributed independently to outcome. Moreover,
when interaction between BRAF V600E and CDKN2A status was
implemented, the combination of BRAF V600E and CDKN2A
deletion predicted recurrence with an HR of 3.2 (P = .03; Table 2).
Similarly, the extent of resection and CDKN2A status were in-
dependent predictors of poor outcome in the BRAF V600E in-
dependent cohort. Five-year PFS for patients with BRAF V600E
and CDKN2A deletion and non-GTR in the SickKids cohort and
independent cohort was 24% (95% CI, 1.9% to 46.1%) and 15%
(95% CI, 0% to 42%) respectively. Using c-statistics analysis, the
addition of BRAF V600E slightly improved the prediction model
expressed by nonsignificant change in area under the curve from
0.814 to 0.826 (P = .668).
BRAF V600E PLGG Responds Favorably to Targeted
Therapy
Six patients with BRAF V600E-mutated PLGG who experi-
enced progression after conventional treatment were treated with
BRAF inhibitors on a compassionate basis. Because targeted
therapies represent a novel and attractive option for progressive
BRAF V600E cancers,20 quantitative imaging findings at 6 months
from initiation of conventional chemotherapy and targeted therapy
were compared for the SickKids cohort and independent cohort. At
6 months, only 23% of tumors revealed an objective response to
chemotherapy (. 25% of tumor shrinkage). Furthermore, up to
24% of the tumors progressed while on therapy, which resulted in
treatment changes. This did not differ between first-line, second-
line, and third-line chemotherapy. Of interest, all six progressive
tumors, which were treated with V600E inhibitors, showed sig-
nificant response (49% to 80% cytoreduction) to targeted therapy
(Fig 3). All six patients remain on V600E inhibitors to date with
a median follow-up of 18.5 months (range, 15 to 36 months). In
one patient, the V600E inhibitor was discontinued after 2 years.
This patient developed a significant tumor progression associated
with clinical deterioration. Therapy was restarted with rapid
clinical and radiologic responses.
Table 2. Multivariable Analysis
Variable HR 95% CI P
SickKids discovery cohort
PFS
BRAF V600E 1.5964 1.0054 to 2.535 .0474
CDKN2A deleted 1.4882 0.9203 to 2.406 .1050
Age 0.9682 0.9251 to 1.013 .1657
Subtotal resection 6.3849 3.7810 to 10.782 4.05 3 10212
Female sex 1.2525 0.8472 to 1.852 .259
Grade 2 1.2084 0.6020 to 2.426 .5944
OS
BRAF V600E 1.1278 0.62 to 2.051 .6936
CDKN2A deleted 0.9681 0.4946 to 1.895 .9246
Age 0.9604 0.9161 to 1.007 .0940
Subtotal resection 6.4670 3.8284 to 10.924 2.98 3 10212
Female sex 1.2235 0.8283 to 1.807 .3108
Grade 2 1.0232 0.5005 to 2.092 .9499
BRAF V600E: CDKN2A 3.2550 1.1332 to 9.35 .0284
Independent cohort
PFS
CDKN2A deleted 2.283 1.25 to 4.170 .00722
Subtotal resection 1.950 1.091 to 3.484 .02414
OS
CDKN2A deleted 4.342 1.0659 to 17.688 .0405
Subtotal resection 1.954 0.4611 to 8.279 .3633
Abbreviations: HR, hazard ratio; OS, overall survival; PFS, progression-free
survival.
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Fig 3. Response of patients with BRAF
V600E pediatric low-grade glioma to chemo-
therapy and BRAF V600E inhibition. Waterfall
plot of response to chemotherapy at 6months.
Note the response to BRAF V600E inhibitors
in gray. PFS, progression-free survival.
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DISCUSSION
This study explores a specific type of molecularly defined sub-
group of PLGG. BRAF V600E is more common than originally
thought in PLGG21—17% of cases—and is relatively common in
previously unrecognized locations, such as the midline. BRAF
V600E confers worse outcomes when treated with chemotherapy
and radiation compared with BRAF WT PLGG, especially when
CDKN2A deletion coexists. It also highlights several important
observations that may affect our approach to and management of
these tumors.
Although BRAF V600E is known to be common in pleo-
morphic xanthoastrocytoma and gangliogliomas,21-23 this muta-
tion is not restricted to those histologic subtypes and is highly
prevalent in diffuse astrocytomas and other low-grade astrocy-
tomas (Table 1). This is in agreement with other smaller series that
have reported V600E in all PLGG subtypes.24,25 Of importance,
BRAF V600E mutation can be found in any location in the CNS,
and . 33% of BRAF V600E-mutant tumors are located in the
midline (diencephalon and brainstem). Tumors in these locations
are often not biopsied, and medical therapy (radiation and che-
motherapy) is initiated blindly under the assumption that all
PLGGs will have similar outcome.26-28 Furthermore, because in
some cases a gray zone exists between low-grade and high-grade
glioma in children, and a histopathologic definition is not uni-
versally suitable to distinguish these, molecular analysis adds an
important dimension to the approach for such tumors. Together,
as BRAF V600E represents a clinically distinct subgroup of PLGG,
current approaches toward the need for biopsy and molecular
testing in PLGG should be re-evaluated.
Overall, our data suggest that BRAF V600E and CDKN2A
deletion constitute a distinct clinical entity within PLGG. First, as
observed in both the SickKids cohort and independent cohort (Fig
2), these tumors are relentless and tend to recur multiple times,
which results in poor outcome, which is dissimilar to other PLGGs.
Extensive clinical follow-up enabled through the Ontario databases
allows for the capture of late deaths observed in patients with BRAF
V600E PLGG. These represent a major burden that extends from
childhood to adult survivors of PLGG.15 These late deaths are
attributed to late progression and tumor transformation up to 25
years after initial diagnosis.11 Second, BRAF V600E PLGGs rep-
resent a distinct entity in their poor outcome after current con-
ventional therapies. After complete resection, typical PLGGs do not
need additional treatment—only 5% of WT tumors with GTR in
the SickKids cohort recurred. One third of BRAF V600E PLGG in
which GTR was achieved recurred in both the SickKids cohort and
independent cohort (Figs 2A and 2B), which suggests different
tumor invasiveness.
For PLGG as a whole, outcome after radiation and chemo-
therapy is associated with PFS . 80% and 50%, respectively, at
5 years in PLGG series.27,29,30 In contrast, the present experience
shows that BRAF V600E PLGGs have , 50% and 35% PFS after
radiation and chemotherapy, respectively, at 5 years (Appendix Fig
A1). Together, this suggests a different tumor type.
CDKN2A alterations are common in many adult cancers,
including gliomas.12,13 It allows for a bypass of cell cycle arrest,
which would normally be initiated by RAS pathway oncogenic
activation.14 In contrast to adult gliomas, TP53 mutations are
uncommon in PLGGs; therefore, CDKN2A alterations may play an
important role in the behavior of some of these tumors. In this
study, CDKN2A deletion conferred poor outcome for patients with
PLGG who harbored the BRAF V600E mutation. The prognostic
value of this alteration was confirmed in the independent cohort.
Combining V600E, CDKN2A, and the extent of resection, we
are able to define a high-risk group of PLGG with, 10% chance of
tumor control and poor survival with conventional therapies.
These survival curves are not observed in other PLGGs, and novel
therapies should be considered for these patients.
Analysis of tumor response within 6 months of initiation in
those who received chemotherapy provided important insight into
the clinical behavior of BRAF V600E PLGG. A significant pro-
portion of these patients had to switch to other chemotherapy
regimens or radiation at 6 months as a result of tumor progression.
This is rarely observed with current PLGG protocols.17,27 Although
the numbers are small and should still be considered anecdotal, all
six patients who were treated with a BRAF V600E inhibitor
achieved a response, with volumetric shrinkage of 49% to 80%
with this targeted therapy. This objective response is encouraging
in view of previous data. Of note, remarkable clinical improvement
was observed in all these heavily pretreated patients.31
Results of clinical trials that used BRAF V600E inhibitors in
patients with PLGG are pending; however, several case reports have
already shown activity of BRAF V600E inhibitors in children with
PLGG.31-35 Although longer follow-up is required to determine
emerging resistance and long-term adverse effects of these drugs,
the rapid responses observed with these therapies in patients with
BRAF V600E PLGG are encouraging and can potentially prevent
ongoing sequelae, such as visual loss and neurologic deterioration,
which are commonly observed with current therapies.
Taken together, these data reveal that BRAF V600E PLGGs are
distinct from other PLGGs and require a different short-term and
long-term therapeutic approach. Upfront diagnosis of these tu-
mors is needed to define prognosis and a decision whether to
include aggressive surgery and early targeted therapies for these
patients. Finally, this study highlights the need for a change in our
overall approach to PLGGs. Consideration for upfront biopsy and
molecular diagnosis of deeply located midline tumors that are
commonly treated without histologic confirmation will allow for
better tailoring of therapeutic interventions and better outcome for
these children in the era of precision medicine.
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Appendix
METHODS
Patient Cohorts
This study was approved by the institutional review board of the Hospital for Sick Children (SickKids). By using our pediatric
low-grade glioma (PLGG) database, we retrospectively identified 517 of 845 patients who were diagnosed at SickKids between 1985
and 2015 for whom both biopsy material and adequate clinical follow-up were available. In all patients, BRAF V600E mutation was
analyzed. Subependymal giant-cell astrocytomas were excluded from the analysis (517 patients – seven patients with subependymal
giant-cell astrocytomas = 510 patients). In those patients who received chemotherapy and had available studies and imaging
(computed tomography and/or magnetic resonance imaging) were compared before initiation of treatment and at 6 months of
receiving treatment to evaluate the response to chemotherapy for each treatment received. Progression was defined as the need for
treatment change related to tumor growth (surgery, chemotherapy, or radiation) after imaging or clinical worsening. To be more
accurate in the analysis of global incidence and the incidence according to location and pathology subtypes, we decided to include in
this analysis only the total number of patients who were diagnosed from year 2000 (N = 449). We were able to obtain a BRAF
mutation status for 90% of patients (n = 405).
Independent Cohort of BRAF V600E-Mutated PLGG
To validate our data of patients with the BRAF V600E-mutation, we retrieved 180 patients with BRAF V600E-mutated PLGG
from 18 collaborating centers from around the world. Clinical data collected included the same variables as in our cohort. In all
samples received, BRAF V600E mutation was performed for confirmation and CDKN2A copy number status was also assessed by
using the same methods as described for our cohort.
Statistical Analysis
To examine the prognostic effect of BRAF V600E, we constructed Cox proportional hazards regression models with and
without BRAF V600E, along with other covariates, such as age, gross total resection, CDKN2A, grade, and sex. Concordance
probability estimate was calculated as an indicator that assessed the overall value of a covariate in predicting a censored outcome and
it was preferred over C-index in the Cox model context. In addition, logistic regression models were performed with and without
BRAF V600E. Corresponding C-index values were calculated.
Biologic Studies.
Immunohistochemistry. Detection of BRAF V600E by immunohistochemistry was performed on our Benchmark Ventana
Machine (Tucson, AZ) using the Optiview detection kit (Tucson, AZ). CC1 was used for heat retrieval for 40 minutes. Thirty-six
minutes of incubation with the Mouse Anti-Human BRAF V600E Monoclonal Antibody from Spring Bioscience (Pleasanton, CA).
Casein was used for 8 minutes to help lessen some background staining and hematoxylin counterstain was used for 12 minutes.
Slides were scored by a senior neuropathologist at SickKids (C.H.).
Nucleic acid isolation. DNA was first isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue using the
MasterPure Complete DNA and RNA Purification Kit (MC85200; Epicentre, Madison, WI) according to manufacturer in-
structions. Total RNA was extracted from FFPE tissue with the RNeasy FFPE extraction kit (Qiagen, Valencia, CA) using
manufacturer guidelines.
Droplet digital PCR—rare event detection. In this study, we used droplet digital (dd) PCR (Bio-Rad, Hercules, CA) to detect the
somatic point mutation c.1799 C.T in the BRAF gene (p.V600E). The rare event detection assay for BRAF V600E was conducted
according to manufacturer instructions. In brief, each 20-mL reaction mixture contained 50 ng DNA, 12.5 mL ddPCR Supermix for
probes (no dUTP; Bio-Rad), 1.25 mL PrimePCR ddPCR mutation assay BRAF WT for p.V600E, Human (unique assay ID:
dHsaCP2000028), 1.25 mL PrimePCR ddPCR mutation assay BRAF p.V600E, Human (unique assay ID: dHsaCP2000027), and
1 mL Fast Digest BsuRI (Thermo Fisher Scientific Life Sciences, Waltham, MA). PCR reaction mixtures were partitioned into an
emulsion of approximately 20,000 uniformly sized droplets. Droplets were then transferred to a 96-well PCR plate, heat sealed, and
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placed in a conventional thermal cycler (C1000 Touch Thermal Cycler; Bio-Rad). Thermal cycling conditions were as follows: 95°C
for 10 minutes, 39 cycles of 94°C for 30 seconds and 55°C for 60 seconds, 98°C for 10 minutes, and a 4°C hold. After PCR, the PCR
plate was loaded on a QX100 droplet reader (QX100 System; Bio-Rad). Analysis of ddPCR data was performed with Quanta-Soft
software (Version 1.6.6; Bio-Rad). Each tumor sample was run in technical duplicates.
ddPCR—copy number variation. We also used ddPCR to assess copy number changes in the gene CDKN2A. The assay was
performed similarly to the rare event detection assay. We used prime PCR ddPCR copy number assay CDKN2A (unique assay ID:
dHsaCP1000581) and a reference prime PCR ddPCR copy number assay APB31 (unique assay ID: dHsaCP2500348). A known
homozygous deleted cell line, AM38, was used as a zero-copy control, whereas an Ontario Population Genomics Platform healthy
control sample (ID: 85751) obtained from The Center of Applied Genomics at SickKids was used as a two-copy control.
Samples that showed, 1.4 copy number value as calculated from the total target and reference event number were considered
deleted (concentration [copies/mL] of target/concentration [copies/mL] of reference 3 expected copy number of diploid genome
2). Each sample was run in technical duplicate, which yielded four data points. Final results were determined as the mean copy
number of data points that belonged to both the target and reference genes. Thermal cycling conditions were as follows: 95°C for 10
minutes, 39 cycles of 94°C for 30 seconds and 60°C for 60 seconds, 98°C for 10 minutes, and a 4°C hold.
NanoString—detection of fusion transcripts. Probes that targeted KIAA1549-BRAF fusion variants were designed in collab-
oration with NanoString (Seattle, WA). Five hundred nanograms of total RNAwas added to the nCounter Elements TagSet (Seattle,
WA) in hybridization buffer and incubated at 67°C for 20 hours. The sample was processed on the nCounter Preparation Station
and the cartridge scanned at 555 fields of view on the nCounter Digital Analyzer. Raw counts were subjected to technical
normalization by using counts obtained for positive control probe sets included in each run. The statistical outlier detection method
was used to detect the presence of an expressed fusion. Data were viewed by using a box plot, and the presence of an extreme outlier
(33 interquartile range) indicates fusion expression.
Fluorescent in situ hybridization. Fluorescent in situ hybridization was designed to detect transcripts by using bacterial artificial
chromosome clones within the duplicated region at 7q34 (RP11-248P7 and RP11-837G3) and 7p12.1 control probes (RP11-
478M17 and RP11-876P22). Probes were obtained from The Centre for Applied Genomics. The 7q34 clones were directly labeled
with Spectrum Green fluorochrome, and control clones were directly labeled with Spectrum Orange fluorochrome. Paraffin
fluorescent in situ hybridization analysis was performed on 4-mm tumor sections. Slides were baked overnight to fix the section to
the slide and were pretreated by using a paraffin pretreatment kit (Abbott, Chicago IL). Sections were dehydrated before slide/probe
codenaturation on thermobrite (Intermedico, Markham, ON, Canada). Denaturation conditions used for paraffin-embedded
slides/probes were as follows: 85°C for 7 minutes, followed by overnight incubation at 37°C. Slides were washed in30.4 side scatter/
0.3% NP-40 at 73°C for 30 seconds, followed by 32 side scatter/0.1% NP-40 at room temperature for 30 seconds. Slides were
counterstained with DAPI. Nuclei were analyzed by using an Axioplan2 epifluorescence microscope (Zeiss, Jena, Germany). Images
were captured by an Axiocam MRm Camera (Imaging Associates, Bicester, United Kingdom) and analyzed by using an imaging
system with Isis Software (Version 5.1.110; MetaSystems, Boston, MA).
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Fig A2. Survival of SickKids patients stratified by CDKN2A status. (A) Progression-free survival (PFS) and (B) overall survival (OS) for all patients from the SickKids cohort
according to CDKN2A status. (C) PFS and (D) OS for patients from the SickKids cohort with wild-type pediatric low-grade glioma (PLGG) according to CDKN2A status. (E)
PFS and (F) OS for patients from the SickKids cohort with BRAF V600E PLGG according to CDKN2A status. P values were determined by using log-rank test.
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Fig A3. (A) Progression-free survival (PFS) for the BRAF V600E independent cohort. (B) Overall survival (OS) for the BRAF V600E independent cohort.
Table A1. BRAF V600E Mutated Patient Characteristics in the SickKids and
Independent Cohorts
Characteristic
SickKids Cohort
(n = 99)
Independent
Cohort (n = 180)
Sex, %
Male/female 53/47 48/52
Median age, years (range) 9.23 (0.23-17.46) 9.33
Location, %
Hemispheres 53.5 52.2
Midline 27.3 23.9
Cerebellar 5.1 11.1
Brainstem 11.1 9.4
Spine 3 0.6
Other 2.8
Diagnosis, %
Pilocytic astrocytoma 12.1 17.2
Pilomyxoid astrocytoma 2 0.6
Ganglioglioma 33.3 32.8
PXA 10.1 18.9
Diffuse astrocytoma 10.1 6.7
LGG NOS 25.3 13.3
Others 7.1 10.5
OS: Median follow-up,
years (range)
5.11 (0.05-27.37) 4.01 (0-24.43)
PFS: Median follow-up,
years (range)
2.69 (0.01-16.03) 2.01 (0-24.43)
% of GTR 44.4 42.7
Received treatment other
than surgery, %
40.4 42.2
Received radiation, % 22.2 23.8
Transformation, % 4 2.7
Abbreviations: GTR, gross total resection; LGG NOS, low-grade glioma not
otherwise specified; OS, overall survival; PFS, progression-free survival; PXA,
pleomorphic xanthoastrocytoma.
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